CingulateCING
CING
About: Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Employees: 13
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
27% more capital invested
Capital invested by funds: $447K [Q4 2024] → $566K (+$119K) [Q1 2025]
0.66% more ownership
Funds ownership: 2.83% [Q4 2024] → 3.49% (+0.66%) [Q1 2025]
0% more funds holding
Funds holding: 9 [Q4 2024] → 9 (+0) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
162%
upside
Avg. target
$36
757%
upside
High target
$61
1,352%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 1,352%upside $61 | Buy Maintained | 27 May 2025 |
Roth Capital Boobalan Pachaiyappan | 162%upside $11 | Buy Maintained | 19 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025
Neutral
GlobeNewsWire
2 months ago
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide
Neutral
GlobeNewsWire
2 months ago
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission
Neutral
GlobeNewsWire
5 months ago
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5 million.
Neutral
GlobeNewsWire
7 months ago
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301
Neutral
GlobeNewsWire
8 months ago
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate's lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercialization, and other therapeutic areas where the company's PTR™ technology may be applied.
Neutral
GlobeNewsWire
9 months ago
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
$10 Million of additional Capital Recently Raised Strengthening Balance Sheet $10 Million of additional Capital Recently Raised Strengthening Balance Sheet
Neutral
GlobeNewsWire
9 months ago
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST.
Neutral
GlobeNewsWire
9 months ago
Cingulate Announces Adjournment of Special Meeting
KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals.
Positive
Invezz
9 months ago
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This dramatic increase is attributed to the company's recent achievement of securing a European patent for CTx-1301, its flagship ADHD treatment.
Charts implemented using Lightweight Charts™